Our chRDNA genome-editing technology fuels innovation

Off-the-shelf CAR-T cell therapies

CAR-T cell therapies have shown great promise in treating blood cancers and autoimmune diseases. Our CAR-T cell therapies are armored for potentially improved activity against diseases and are designed to reach a broad number of patients with off-the-shelf treatment options.

CAR-T cell therapy platform

Scientific publications

Recent publications

Improved genome editing with Cas12a and Cas9 chRDNA platform in T, NK, B, and iPS cells
Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. February 21-24, 2024.

Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells
Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT). May 16, 2022.

chRDNA and CRISPR

Improved genome editing with Cas12a and Cas9 chRDNA platform in T, NK, B, and iPS cells
Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. February 21-24, 2024.

Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells
Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT). May 16, 2022.

Advances in industrial biotechnology using CRISPR-Cas systems
Trends in Biotechnology. February 1, 2018.

CB-010

CB-011

CB-012

Other

CB-020, an Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic CAR-NK Cell Therapy, Engineered for Enhanced Activity Against Solid Tumors
12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research – Translating Knowledge into Practice. December 10-14, 2022.